We are an innovative research organization with decades of experience in translating nascent science into leading edge drug discovery programs. We provide expert support across the drug discovery pipeline, offering integrated and stand-alone services to our partners in key therapeutic areas including cancer, neurological disorders, infection, and rare diseases.
Since our establishment as the Italian site of Merck & Co’s Research Laboratories in 2000, we have built an unprecedented track record of success in drug discovery with four therapeutics, discovered by IRBM scientists, currently on the market. Since becoming independent in 2010, we have collaborated with many of the world’s top pharmaceutical and biotechnology companies, as well as global foundations and life science organisations such as MD Anderson Cancer Centre and CHDI Foundation Inc. In 2022, we were selected to join the Chemical Biology Consortium, part of the National Cancer Institute Experimental Therapeutics (Next) Program to help address unmet need in therapeutic oncology.
Our expertise in infectious disease research has been acknowledged with significant funding from the European Investment Bank and our research has led to the out-licencing of fourth-generation Hepatis B Capsid Assembly modulators, which we developed together with our long-standing Italian collaborators the National Institute of Molecular Genetics, and the San Raffaele Hospital.